BioNxt的阿尔茨海默氏病药物在试验中显示出有希望, BioNxt's Alzheimer’s drug showed promise in trials, prompting plans for FDA submission and a larger study.

生物技术公司BioNxt Development(BioNxt Development)今天宣布,它对早期阿尔茨海默氏病的实验治疗在第二阶段临床试验中取得了有希望的成果,参与者显示认知功能有所改善,与安慰剂组相比,疾病进展速度较慢。 BioNxt Advances, a biotechnology company, announced today that its experimental treatment for early-stage Alzheimer’s disease has shown promising results in a Phase 2 clinical trial, with participants demonstrating improved cognitive function and slower disease progression compared to the placebo group. 该公司计划在2026年初向林业发展局提交数据,以供加速核准,并启动规模更大的第三阶段试验。 The company plans to submit data to the FDA for accelerated approval and initiate a larger Phase 3 trial in early 2026.